Title
Date
- Running Bispecific Antibody and T-Cell Engager Trials in Korea: A Sponsor’s Regulatory and Operational Playbook
- FDA and EMA’s 2026 AI and Bayesian Guidance: What the New Regulatory Convergence Means for Clinical Trial Design in Korea
- Is Your Combination Product Drug-Led or Device-Led in Korea? A Sponsor’s Guide to MFDS Classification and Dual-Track Review
- The First PROTAC Drug is Now FDA-Approved: What Vepdegestrant’s 2026 Breakthrough Means for the Next Wave of Targeted Protein Degradation Trials
- GLP-1 Drugs and Cancer: What ASCO 2026 Data Means for Oncology Clinical Trials in Korea
- What Global Biotechs Need Before Entering Korea in 2026
- Why Site Contract Negotiation Often Delays Korea Clinical Trial Startup in 2026
- Operational Differences Between Korea and US Clinical Trials: What Global Sponsors Must Understand in 2026
- 2026 Korea Clinical Trial Operations Guide: How Korean Hospitals Handle Global Clinical Trials and International Sponsor Execution
- Strategic Navigation of 2026: A Comprehensive Guide to Accelerating Cell and Gene Therapy (CGT) Approvals under the New MFDS Regulatory Framework in South Korea